The medicine is relevant for easing symptoms related to physical discomfort at the skin surface prior to specific superficial procedures. It is commonly used for managing symptoms associated with temporary, localized discomfort during superficial dermatological procedures. The medicine is indicated for providing temporary, localized numbing of the skin for superficial dermatological procedures.

Support for Dermatologic and Aesthetic Procedures

This numbing cream is commonly used in clinical settings to manage the acute discomfort associated with various dermatologic and cosmetic interventions. This domain encompasses procedures such as dermal filler injections, certain types of laser treatments (like facial resurfacing or hair removal), and treatments involving laser-assisted tattoo removal. The benefit is providing supportive symptomatic relief that may assist with patient comfort during the intervention.

The medicine is applied in addressing the acute cluster of superficial pain, stinging, and burning sensations that accompany minor skin procedures. By easing this expected procedural discomfort, the medicine supports the patient during difficult episodes by easing distress. This focused symptomatic support is relevant for both adults and patients with heightened pain sensitivity.

“The core benefit is providing support that helps ease the overall symptom burden.”

---

Quick Fact: Relief for Acute Procedural Pain The medicine is used for managing symptoms related to physical discomfort at the skin surface associated with acute or episodic changes.

---

Eligibility Map: Who Can and Cannot Use Pliaglis — Official Regulatory Information

Eligibility Scope

Category	Regulatory Statement
Populations for whom use is allowed	Adults (18 years and older) for use on intact skin prior to superficial dermatological procedures.
Populations for whom use is contraindicated	Patients with known sensitivity to lidocaine, tetracaine, local anesthetics of the amide or ester type, PABA (a tetracaine metabolite), or other components.
	Patients with congenital or idiopathic methemoglobinemia.
Age-related eligibility rules	Pediatric patients (under 18 years): Safety and efficacy have not been established. Use is not recommended or not indicated in this age group.
Condition-specific eligibility rules	Use with caution in patients with severe hepatic disease or pseudocholinesterase deficiency due to impaired drug metabolism.
	Use with caution in patients with conditions that increase susceptibility to methemoglobinemia, such as G6PD deficiency, or in the acutely ill/debilitated.
Pregnancy and lactation eligibility status	Pregnancy: Use should be considered only if the benefits outweigh the risks; caution is advised. Lactation: Breastfeeding can continue, but the cream must not be applied to the breast or nipple area.
Eligibility-related restrictions	Use is strictly prohibited on mucous membranes and areas with a compromised skin barrier (e.g., broken, irritated, or inflamed skin) due to risk of increased systemic absorption and toxicity.

---

Connection to the Overall Eligibility Profile

The official eligibility profile for Pliaglis is defined by strict contraindications against hypersensitivity and certain blood disorders. Use is fundamentally restricted to adults on intact skin because pediatric safety is not established and application to broken skin or membranes can lead to high systemic drug absorption. Patients with impaired drug metabolism, such as those with severe hepatic disease, require mandatory caution due to a higher risk of developing toxic plasma concentrations.

Interactions with other medicines and products

Official regulatory information for Pliaglis (lidocaine and tetracaine) cream focuses primarily on interactions that increase the risk of systemic toxicity rather than metabolic interference.

Documented Interaction Patterns

The most critical documented interaction involves the additive and potentially synergistic systemic toxic effects when Pliaglis is used concurrently with other local anesthetic agents or specific antiarrhythmic medicinal products. Regulatory documents classify the co-administration with Class I and Class III antiarrhythmic drugs (such as Tocainide, Mexiletine, or Amiodarone) as requiring caution, as the overall systemic load of anesthetic agents must be considered.

Another significant risk is a pharmacodynamic interaction with oxidizing agents, which increases the chance of a methemoglobinemia-related adverse reaction. These agents include specific Nitrates, Nitrites (e.g., Nitroglycerin, Nitroprusside), and certain Sulfonamides or Dapsone.

Restrictions and Population-Specific Considerations

The product is contraindicated in patients with a known history of sensitivity to the active ingredients or to Para-aminobenzoic acid (PABA) hypersensitivity, a metabolite of tetracaine.

Classification	Regulatory Status
Additive Systemic Toxicity	Use with caution, total dose consideration required
Metabolite-Related Sensitivity	Formal contraindication

Regulatory documentation also notes that patients with severe hepatic disease or pseudocholinesterase deficiency face a greater risk of developing toxic plasma concentrations, which heightens the potential severity of all systemic drug interactions due to impaired clearance.

Voltage-Gated Sodium Channel Blockade

Pliaglis exerts its effect by acting on Voltage-Gated Sodium Channels ( Nav) located on peripheral sensory neurons. The active ingredients, Lidocaine and Tetracaine, physically enter and obstruct the internal pore of the ion channel. This interaction is a use-dependent, non-depolarizing blockade that prevents the crucial inward flux of sodium ions ( Na^+) necessary for cellular depolarization. This action directly reduces the electrical excitability of the nerve membrane, suppressing the further propagation of the afferent neural impulse.

---

Interruption of Peripheral Nociceptive Conduction

The inhibition of Na^+ influx prevents the nerve from generating an action potential, resulting in a reversible conduction block. This interruption of the signal pathway creates a localized, functional barrier that prevents sensory signals from the application site from reaching the central nervous system, leading to a temporary abolition of sensory nerve function.

---

Kinetic Synergy and Optimized Delivery

The formulation utilizes the complementary kinetics of Lidocaine (associated with rapid onset) and Tetracaine (associated with prolonged duration) in a eutectic mixture. This synergy supports a rapid establishment and sustained maintenance of the nerve conduction interruption.

Administration and Dosage Principles

The usage of Pliaglis Cream is based on a single-application protocol for adult patients and is applied exclusively by the topical route. The medicine is indicated only for use on intact skin and is not to be applied to broken skin, mucous membranes, or near the eyes.

Key Dosing Limits and Application Time

Dosing principles center on limiting the total drug exposure. The cream is applied in a thin, even layer, approximately 1 mm thick, and the total area treated must not exceed 400 cm^2 in a single session. The safety and effectiveness of using more than one application have not been established.

Application Duration	Procedural Context
20 to 30 minutes	Common superficial procedures (e.g., dermal filler injections)
60 minutes	Longer or more intensive procedures (e.g., laser-assisted tattoo removal)

The cream forms a flexible, self-occluding film that should not be covered by an additional dressing. The precise application time, which may not be exceeded, is followed by the film's mandatory removal before the procedure begins.

Population Constraint

Pliaglis is not indicated for use in pediatric patients (individuals under 18 years of age), as safety and efficacy data are unavailable for this population.

Recent Clinical Evidence

Pliaglis (lidocaine 7% and tetracaine 7%) is a topical local anesthetic cream indicated for use on intact skin in adults to provide local analgesia for superficial dermatological procedures. Its formulation is designed to dry into a peelable, self-occluding film, which eliminates the need for a separate occlusive dressing.

---

Clinical Efficacy Studies

Multiple randomized, controlled trials (RCTs) have investigated the cream's performance for procedures such as laser-assisted hair removal, dermal filler injections, pulsed dye laser therapy, and facial laser resurfacing.

• Placebo-Controlled Trials: Studies consistently reported statistically significantly lower pain scores in subjects treated with the active cream compared to those treated with a placebo (vehicle) cream, as measured by a Visual Analog Scale (VAS).
• Procedural Use: In various clinical settings, a majority of patients and investigators reported that the cream provided adequate pain relief for the specific dermatological procedure being performed.

---

Pharmacokinetic and Safety Profiles

Research has explored the systemic exposure and safety of the active ingredients, lidocaine and tetracaine, following topical application.

• Systemic Absorption: Systemic exposure to lidocaine was found to be proportional to the area of application and increased with the duration of application up to 60 minutes. Tetracaine plasma levels were generally found to be unmeasurable due to its rapid hydrolysis in the plasma.
• Adverse Events: Local reactions at the application site are the most frequently reported adverse events in studies, commonly including transient and mild erythema (redness), pruritus (itching), and blanching (skin whitening). Serious systemic adverse events were reported to be rare in clinical trials when the cream was used according to specified application guidelines.

Common questions about Pliaglis (FAQ)

Q: How is Pliaglis different from other lidocaine/tetracaine creams?

A: Pliaglis is uniquely formulated as a cream that dries after application to form a peelable, self-occluding film. This feature is noted in the product information. This film supports the localized delivery of the active ingredients, which is the intended mechanism for numbing, and eliminates the need for an external occlusive dressing that is often required when using other topical anesthetic creams.

Q: Can Pliaglis be used for piercings or waxing?

A: Official regulatory documents indicate Pliaglis is only intended for use on intact skin prior to superficial dermatological procedures, such as dermal filler injections or laser treatments. Safety and effectiveness have not been established for use with procedures other than those listed in the official label.

Q: Does Pliaglis help with nerve pain or only superficial procedures?

A: Pliaglis is indicated specifically to provide topical local analgesia (localized pain relief) on the skin's surface for superficial procedures. It is not indicated for the treatment of chronic or neuropathic pain, as its indication is limited to local dermal analgesia for superficial procedures.

Q: Is it normal to feel a tingling or warm sensation when Pliaglis is applied?

A: While the most common localized skin reactions are redness, swelling, and skin discoloration, the product label does note that less common reactions or signs of overexposure can include sensations such as heat, cold, or paresthesia (a tingling or prickling sensation). Patients who experience a burning sensation are advised to discontinue use and remove the cream, according to safety information.

Q: How long does the numbing effect last after the Pliaglis film is peeled off?

A: Official dosing instructions are focused on the duration the cream must be applied to the skin (20 to 60 minutes) to achieve adequate numbing before a procedure. The exact duration of pain relief after the film is removed and the procedure is completed is not explicitly defined in the official prescribing information.

Q: Can the area treated with Pliaglis be larger than the official guidelines suggest?

A: No. The official dosing information strictly specifies that the maximum application area must not exceed 400 cm^2 in a single session. Applying the cream over a larger surface area than recommended is associated with an increased risk of excessive systemic absorption and adverse effects.

Q: Does Pliaglis interact with alcohol applied to the skin?

A: Regulatory documents primarily focus on drug-drug interactions, such as those with other local anesthetics and specific antiarrhythmic medicines. There is no specific documentation or study cited in the product information regarding interactions with routine topical alcohol products.

Q: Is Pliaglis safe for people who are pregnant or breastfeeding?

A: Official labeling advises that Pliaglis should be used during pregnancy only if the potential benefit justifies the potential risk. For nursing mothers, the official label advises that the cream must not be applied to the breast or nipple area, although breastfeeding may otherwise continue.

Q: What happens if the Pliaglis film cracks or peels off too early?

A: The cream must be left on for the full application duration (up to 60 minutes) to achieve the necessary pain relief. Official labeling suggests that a shorter application time, such as that caused by premature film removal, may result in less complete or shorter-duration pain relief than desired for the procedure.

Q: Does the efficacy of Pliaglis change if the skin is cold or hot?

A: The product labeling includes a specific warning against exposing the application site to external heat sources. Heat may increase the absorption of the active drug ingredients, which is associated with an increased risk of systemic toxicity.

Q: Can Pliaglis be used to numb the skin before getting a vaccine or blood draw?

A: Pliaglis is indicated for use before superficial dermatological procedures, and the label does not specifically address all needle-stick procedures. Official regulatory guidance lists examples such as dermal filler injection and laser procedures.

Q: Does Pliaglis work for pain related to shingles or other rashes?

A: Pliaglis is indicated only for local dermal analgesia on intact skin and is specifically contraindicated on areas with a compromised skin barrier, such as rashes or irritated skin. It is not indicated for the treatment of pain associated with shingles or other skin conditions, as its use is restricted to local dermal analgesia on intact skin.

Q: What is the shelf life of an open tube of Pliaglis?

A: According to the official product information, once a tube of Pliaglis is first opened, it must be used within 3 months (90 days). It is also required to be stored safely in a refrigerator and must not be frozen.

Pliaglis Cream requires specific conditions to maintain its efficacy and ensure safety, as defined by regulatory labeling.

Official Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator (2°C to 8°C or 36°F to 46°F).
Handling	Do not freeze the cream. Replace the cap securely after each use.
Stability	Once opened, the product must be used within 3 months (90 days).

Disposal and Safety Rules

All Pliaglis, including unused product and the used, peelable film, must be stored and disposed of out of the reach of children and pets due to the risk of accidental exposure. Disposal of waste material and unused product must be done in accordance with local requirements for pharmaceutical waste. Medicines must not be discarded via wastewater.